Results 21 to 30 of about 10,442 (179)

Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma

open access: yesScientific Reports, 2021
B7-H3 (also known as CD276) is associated with aggressive characteristics in various cancers. Meanwhile, in alveolar rhabdomyosarcoma (ARMS), PAX3-FOXO1 fusion protein is associated with increased aggressiveness and poor prognosis.
Takuyo Kanayama   +7 more
doaj   +1 more source

PAX3 expression in primary melanomas and nevi [PDF]

open access: yesModern Pathology, 2008
Melanoma is responsible for an estimated 62,000 new American cancer diagnoses and is projected to cause nearly 8000 deaths in 2008 alone. Although the histogenesis of the tumor is not well understood, it is thought to originate from a rare melanocyte stem cell that resides in the skin.
Rebecca S, Plummer   +6 more
openaire   +2 more sources

The characterisation of Pax3 expressant cells in adult peripheral nerve. [PDF]

open access: yesPLoS ONE, 2013
Pax3 has numerous integral functions in embryonic tissue morphogenesis and knowledge of its complex function in cells of adult tissue continues to unfold. Across a variety of adult tissue lineages, the role of Pax3 is principally linked to maintenance of
Judith A Blake, Melanie R Ziman
doaj   +1 more source

Identification of Target Genes Regulated by PAX3 and PAX3–FKHR in Embryogenesis and Alveolar Rhabdomyosarcoma

open access: yesGenomics, 2002
PAX3 is a transcription factor important for neural, muscle, and facial development in vertebrates. To identify genes regulated by PAX3, we used a cyclic amplification and selection of targets (CASTing) strategy to isolate cis-regulatory elements bound by PAX3.
Thomas D, Barber   +5 more
openaire   +2 more sources

PAX3-FOXO1: Zooming in on an “undruggable” target

open access: yesSeminars in Cancer Biology, 2018
Driver oncogenes are prime targets for therapy in tumors many of which, including leukemias and sarcomas, express recurrent fusion transcription factors. One specific example for such a cancer type is alveolar rhabdomyosarcoma, which is associated in the majority of cases with the fusion protein PAX3-FOXO1.
Wachtel, Marco, Schäfer, Beat W
openaire   +3 more sources

Pax3 and Hippo Signaling Coordinate Melanocyte Gene Expression in Neural Crest

open access: yesCell Reports, 2014
Summary: Loss of Pax3, a developmentally regulated transcription factor expressed in premigratory neural crest, results in severe developmental defects and embryonic lethality.
Lauren J. Manderfield   +9 more
doaj   +1 more source

A Pax3/Dmrt2/Myf5 regulatory cascade functions at the onset of myogenesis. [PDF]

open access: yesPLoS Genetics, 2010
All skeletal muscle progenitor cells in the body derive from the dermomyotome, the dorsal epithelial domain of developing somites. These multipotent stem cells express Pax3, and this expression is maintained in the myogenic lineage where Pax3 plays an ...
Takahiko Sato   +4 more
doaj   +1 more source

PAX3‐FOXO1 Directed Transcriptional Activation is Mediated by PAX3 and FOXO1 Recognition Sequences

open access: yesThe FASEB Journal, 2015
Alveolar Rhabdomyosarcoma (ARMS) patients carrying a chromosomal translocation of PAX3 and FOXO1 have the highest mortality rates, indicating the importance of understanding how this transcription ...
Tess Cherlin   +2 more
openaire   +1 more source

Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR–dependent motility in alveolar rhabdomyosarcoma cells

open access: yesBMC Cancer, 2012
Background Alveolar rhabdomyosarcoma (ARMS) has a high propensity to metastasize, leading to its aggressiveness and a poor survival rate among those with the disease. More than 80% of aggressive ARMSs harbor a PAX3-FKHR fusion transcription factor, which
Liu Lingling   +4 more
doaj   +1 more source

Melanoma biomolecules: independently identified but functionally intertwined

open access: yesFrontiers in Oncology, 2013
The majority of patients diagnosed with melanoma present with thin lesions and generally these patients have a good prognosis. However, 5% of patients with early melanoma (< 1mm thick) will have recurrence and die within 10 years, despite no evidence ...
Danielle Erin Dye   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy